Amplifica Holdings Group
United States · Biotech
Amplifica develops injectable drug candidates intended to reactivate hair follicles in people with androgenetic alopecia.
Drug development focused on hair follicles
Amplifica is a clinical-stage biopharmaceutical company developing injectable treatments for androgenetic alopecia in men and women. Its research focuses on signaling molecules involved in the hair-follicle growth cycle, with the aim of reactivating dormant follicles and supporting new hair growth.
A pipeline of different biological approaches
The company is developing several programs that address hair regeneration through different mechanisms, including AMP-303 and earlier-stage candidates. Its work combines molecule discovery, product development and clinical evaluation. The programs are investigational: the company is studying their safety and efficacy as part of a drug-development pathway.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series B | $26M | Tasso Partners — LeadEli Lilly and Company — Participant |